GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » PB Ratio

Chordate Medical Holding AB (OSTO:CMH) PB Ratio : 1.31 (As of May. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Chordate Medical Holding AB's share price is kr0.064. Chordate Medical Holding AB's Book Value per Share for the quarter that ended in Dec. 2023 was kr0.05. Hence, Chordate Medical Holding AB's PB Ratio of today is 1.31.

The historical rank and industry rank for Chordate Medical Holding AB's PB Ratio or its related term are showing as below:

OSTO:CMH' s PB Ratio Range Over the Past 10 Years
Min: 1.06   Med: 3.95   Max: 9.19
Current: 1.32

During the past 9 years, Chordate Medical Holding AB's highest PB Ratio was 9.19. The lowest was 1.06. And the median was 3.95.

OSTO:CMH's PB Ratio is ranked better than
71.34% of 792 companies
in the Medical Devices & Instruments industry
Industry Median: 2.235 vs OSTO:CMH: 1.32

During the past 12 months, Chordate Medical Holding AB's average Book Value Per Share Growth Rate was 4.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -40.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -37.40% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Chordate Medical Holding AB was 29.80% per year. The lowest was -59.60% per year. And the median was -40.55% per year.

Back to Basics: PB Ratio


Chordate Medical Holding AB PB Ratio Historical Data

The historical data trend for Chordate Medical Holding AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB PB Ratio Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only - - - 8.42 2.49

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.42 3.20 3.39 2.91 2.49

Competitive Comparison of Chordate Medical Holding AB's PB Ratio

For the Medical Devices subindustry, Chordate Medical Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's PB Ratio falls into.



Chordate Medical Holding AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chordate Medical Holding AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.064/0.049
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Chordate Medical Holding AB  (OSTO:CMH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Chordate Medical Holding AB PB Ratio Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines